Nantkwest (NASDAQ:NK)‘s stock had its “hold” rating reiterated by analysts at Raymond James Financial in a report issued on Monday.

NK has been the topic of a number of other research reports. Zacks Investment Research raised Nantkwest from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, November 14th. Citigroup set a $3.00 price target on Nantkwest and gave the company a “sell” rating in a research report on Monday, August 14th. Finally, BidaskClub lowered Nantkwest from a “sell” rating to a “strong sell” rating in a research report on Friday, September 22nd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $5.13.

Shares of Nantkwest (NK) traded down $0.01 during trading on Monday, reaching $4.95. The company had a trading volume of 224,900 shares, compared to its average volume of 368,420. Nantkwest has a 12 month low of $2.71 and a 12 month high of $8.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47.

In other news, Director Steve Gorlin sold 39,604 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $5.93, for a total transaction of $234,851.72. Following the sale, the director now owns 246,280 shares of the company’s stock, valued at approximately $1,460,440.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 70.19% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of NK. Renaissance Technologies LLC increased its position in Nantkwest by 1,884.1% during the first quarter. Renaissance Technologies LLC now owns 486,100 shares of the biotechnology company’s stock worth $1,726,000 after buying an additional 461,600 shares during the period. Vanguard Group Inc. increased its position in Nantkwest by 8.4% during the first quarter. Vanguard Group Inc. now owns 2,082,706 shares of the biotechnology company’s stock worth $7,394,000 after buying an additional 160,510 shares during the period. Northern Trust Corp increased its position in Nantkwest by 67.8% during the second quarter. Northern Trust Corp now owns 304,062 shares of the biotechnology company’s stock worth $2,308,000 after buying an additional 122,906 shares during the period. State Street Corp increased its position in Nantkwest by 52.9% during the second quarter. State Street Corp now owns 341,007 shares of the biotechnology company’s stock worth $2,589,000 after buying an additional 117,946 shares during the period. Finally, Alps Advisors Inc. acquired a new position in Nantkwest during the second quarter worth approximately $563,000. 19.14% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Nantkwest’s (NK) Hold Rating Reaffirmed at Raymond James Financial” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/11/nantkwests-nk-hold-rating-reaffirmed-at-raymond-james-financial.html.

About Nantkwest

Receive News & Ratings for Nantkwest Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest Inc and related companies with MarketBeat.com's FREE daily email newsletter.